Sarepta Therapeutics Inc
SRPT24.450USD
+0.440+1.83%
Fechamento 11/03, 16:00（ET）Cotações atrasadas em 15 min
2.39BValor de mercado
PerdaP/L TTM
Mais detalhes de Sarepta Therapeutics Inc Empresa
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Informações de Sarepta Therapeutics Inc
Código da empresaSRPT
Nome da EmpresaSarepta Therapeutics Inc
Data de listagemJun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Número de funcionários1372
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 04
Endereço215 First Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone16172744000
Sitehttps://www.sarepta.com/
Código da empresaSRPT
Data de listagemJun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Executivos da empresa Sarepta Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Ms. Cristin L. Rothfuss
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Por EmpresaUSD
Nome
Receita
Proporção
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
Por RegiãoUSD
Nome
Receita
Proporção
United States
484.77M
94.48%
Rest of World
28.35M
5.52%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
Distribuição de ações
Atualizado em: sáb, 1 de nov
Atualizado em: sáb, 1 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Investment Management (US)
4.49%
Two Sigma Investments, LP
3.96%
Outro
67.15%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Investment Management (US)
4.49%
Two Sigma Investments, LP
3.96%
Outro
67.15%
Tipos de investidores
Investidores
Proporção
Investment Advisor
31.26%
Investment Advisor/Hedge Fund
20.40%
Hedge Fund
20.05%
Research Firm
5.54%
Individual Investor
4.67%
Bank and Trust
1.24%
Pension Fund
1.13%
Sovereign Wealth Fund
0.90%
Insurance Company
0.03%
Outro
14.78%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
1017
84.37M
80.60%
-20.51M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
10.64M
10.17%
+1.51M
+16.51%
Aug 29, 2025
BlackRock Institutional Trust Company, N.A.
9.84M
9.4%
+937.08K
+10.53%
Jun 30, 2025
D. E. Shaw & Co., L.P.
5.06M
4.83%
+581.27K
+12.98%
Jul 18, 2025
State Street Investment Management (US)
4.70M
4.49%
+626.55K
+15.40%
Jun 30, 2025
Two Sigma Investments, LP
4.15M
3.96%
+3.31M
+397.77%
Jun 30, 2025
Barry (Richard J)
3.21M
3.07%
+32.60K
+1.02%
May 16, 2025
Wellington Management Company, LLP
2.53M
2.42%
-116.16K
-4.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.88M
1.79%
+55.08K
+3.02%
Jun 30, 2025
Erste Asset Management GmbH
1.62M
1.55%
+560.35K
+52.81%
Jun 30, 2025
Qube Research & Technologies Ltd
1.60M
1.53%
+1.57M
+4909.63%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: seg, 6 de out
Atualizado em: seg, 6 de out
Nome
Proporção
First Trust NYSE Arca Biotechnology Index Fund
3.25%
iShares Neuroscience and Healthcare ETF
1.62%
Invesco S&P SmallCap Health Care ETF
1.21%
Global X Genomics & Biotechnology ETF
1.11%
Virtus LifeSci Biotech Products ETF
0.81%
Invesco S&P SmallCap 600 Pure Growth ETF
0.66%
SPDR S&P Biotech ETF
0.65%
WisdomTree BioRevolution Fund
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.4%
VanEck Biotech ETF
0.35%
Ver Mais
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.25%
iShares Neuroscience and Healthcare ETF
Proporção1.62%
Invesco S&P SmallCap Health Care ETF
Proporção1.21%
Global X Genomics & Biotechnology ETF
Proporção1.11%
Virtus LifeSci Biotech Products ETF
Proporção0.81%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção0.66%
SPDR S&P Biotech ETF
Proporção0.65%
WisdomTree BioRevolution Fund
Proporção0.43%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.4%
VanEck Biotech ETF
Proporção0.35%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
